Literature DB >> 35692473

In vitro efficacy of polymer coated miltefosine drug against leishmania tropica.

Mehvish Khokhar1, Muhammad Adnan Shereen1, Momin Khan1, Rahat Ullah Khan1, Aamir Sohail1, Imdad Ullah Khan2, Inam Ullah Khan2, Saadullah Khattak3.   

Abstract

Polymer based nanoparticles for drug delivery is an alternative approach to overcome drug resistance and drug toxicity especially for cutaneous leishmaniasis treatment. The present study shows synthesis and characterization of Miltefosine loaded chitosan nanoparticles (MFS-CNPs). The synthesized MFS-CNPs were experimented to evaluate the in vitro cytotoxicity and efficacy of the synthesized drug loaded nanoparticles by hemolysis assay and 3-(4, 5- dimethylthiazol-2-yl)-2,5-diphenyletetrazolium bromide (MTT) assay. MFS-CNPs were synthesized by ionic gelation method with sodium tripolyphosphate. The characterization of synthesized NPs was performed to observe the surface morphology, encapsulation efficacy, drug loading content, average size, and zeta potential. In vitro MTT assay was performed to calculate half maximal inhibitory concentration value of synthesized nanoparticles against promastigotes and axenic amastigotes of L. tropica. By using Scanning electron microscope, MFS-CNPs displayed spherical shape having a mean size of 70 nm along with high EE (97%), DLC (91%) and negative surface charge (- 28.0 mV). Dynamic light scattering shows the average size of NPs was 91.4 nm. Moreover, less than 5% hemolytic activity was observed in MFS-CNPs as compared to free MFS in different concentrations (100 μg/ml, 125 μg/ml, 150 μg/ml).It was observed that the effect of MFS-CNPs and free MFS on both forms of the parasite was dose and time dependent. However, the cytotoxic effects of MFS-CNPs were more salient than free MFS on both forms of L. tropica. Using MTT assay, free MFS presented low efficacy at higher concentrations (30 µg/ml) with 21.4 ± 1.3 and 20.5 ± 1.4 mean viability rate of the promastigotes and axenic amastigotes, respectively after 72 h incubation. While MFS-CNPs showed strong antileishmanial effects on both forms of L. tropica (11 ± 0.3 and 14 ± 0.8) mean viability rate after 72 h incubation at (30 µg/ml). When analyzed statistically by the software, Graph Pad Prism version 5, the IC50 value of MFS-CNPs (0.0218 ± 0.01 µg/ml) against promastigotes was effective than free MFS (0.3548 ± 0.17 µg/ml). Similarly, MFS-CNPs activity against axenic amastigotes (0.1008 ± 0.02 µg/ml) was potent than free MFS (0.5320 ± 0.21 µg/ml). Hence, MFS-CNPs exhibited significant antileishmanial activity in vitro. In conclusion, MFS-CNPs manifested enhanced in vitro Leishmanicidal and less hemolytic activity; however more studies are needed to support its efficacy in both animal and human cutaneous leishmaniasis. © Indian Society for Parasitology 2021.

Entities:  

Keywords:  Chitosan nanoparticles; Hemolysis assay; Leishmania tropica; MTT assay; Miltefosine

Year:  2021        PMID: 35692473      PMCID: PMC9177920          DOI: 10.1007/s12639-021-01452-4

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  49 in total

Review 1.  A review of drug release mechanisms from nanocarrier systems.

Authors:  Chizhu Ding; Zibiao Li
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2017-03-18       Impact factor: 7.328

Review 2.  Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Authors:  Fabiana Alves; Graeme Bilbe; Séverine Blesson; Vishal Goyal; Séverine Monnerat; Charles Mowbray; Gina Muthoni Ouattara; Bernard Pécoul; Suman Rijal; Joelle Rode; Alexandra Solomos; Nathalie Strub-Wourgaft; Monique Wasunna; Susan Wells; Eduard E Zijlstra; Byron Arana; Jorge Alvar
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

3.  The cytotoxic activity of miltefosine against Leishmania and macrophages is associated with dynamic changes in plasma membrane proteins.

Authors:  Kelly Souza Fernandes; Paulo Eduardo Narcizo de Souza; Miriam Leandro Dorta; Antonio Alonso
Journal:  Biochim Biophys Acta Biomembr       Date:  2016-10-20       Impact factor: 3.747

4.  In Vitro Methods for Assessing Nanoparticle Toxicity.

Authors:  Dustin T Savage; J Zach Hilt; Thomas D Dziubla
Journal:  Methods Mol Biol       Date:  2019

5.  Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis.

Authors:  Iqra Afzal; Hafiz Shoaib Sarwar; Muhammad Farhan Sohail; Sanjay Varikuti; Sarwat Jahan; Sohail Akhtar; Masoom Yasinzai; Abhay R Satoskar; Gul Shahnaz
Journal:  Nanomedicine (Lond)       Date:  2019-01-28       Impact factor: 5.307

6.  Uptake of synthetic Low Density Lipoprotein by leukemic stem cells--a potential stem cell targeted drug delivery strategy.

Authors:  Peixun Zhou; Sophia Hatziieremia; Moira A Elliott; Linda Scobie; Claire Crossan; Alison M Michie; Tessa L Holyoake; Gavin W Halbert; Heather G Jørgensen
Journal:  J Control Release       Date:  2010-09-22       Impact factor: 9.776

Review 7.  Chitosan based hydrogels: characteristics and pharmaceutical applications.

Authors:  F Ahmadi; Z Oveisi; S Mohammadi Samani; Z Amoozgar
Journal:  Res Pharm Sci       Date:  2015 Jan-Feb

Review 8.  Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Authors:  Anke E Kip; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

Review 9.  Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.

Authors:  Alicia Ponte-Sucre; Francisco Gamarro; Jean-Claude Dujardin; Michael P Barrett; Rogelio López-Vélez; Raquel García-Hernández; Andrew W Pountain; Roy Mwenechanya; Barbara Papadopoulou
Journal:  PLoS Negl Trop Dis       Date:  2017-12-14

10.  Potent antileishmanial activity of chitosan against Iranian strain of Leishmania major (MRHO/IR/75/ER): In vitro and in vivo assay.

Authors:  Bahman Rahimi Esboei; Mehdi Mohebali; Parisa Mousavi; Mahdi Fakhar; Behnaz Akhoundi
Journal:  J Vector Borne Dis       Date:  2018 Apr-Jun       Impact factor: 1.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.